Denali Therapeutics, Inc. (DNLI)
18.00
-0.08
(-0.47%)
USD |
NASDAQ |
Nov 17, 16:00
18.00
0.00 (0.00%)
After-Hours: 20:00
Denali Therapeutics Enterprise Value : 2.417B for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 2.417B |
| November 13, 2026 | 2.522B |
| November 12, 2026 | 2.546B |
| November 11, 2026 | 2.681B |
| November 10, 2026 | 2.700B |
| November 09, 2026 | 2.777B |
| November 06, 2026 | 2.735B |
| November 05, 2026 | 2.679B |
| November 04, 2026 | 2.878B |
| November 03, 2026 | 2.636B |
| November 02, 2026 | 2.542B |
| October 30, 2026 | 2.554B |
| October 29, 2026 | 2.615B |
| October 28, 2026 | 2.610B |
| October 27, 2026 | 2.599B |
| October 26, 2026 | 2.509B |
| October 23, 2026 | 2.469B |
| October 22, 2026 | 2.509B |
| October 21, 2026 | 2.513B |
| October 20, 2026 | 2.553B |
| October 19, 2026 | 2.410B |
| October 16, 2026 | 2.341B |
| October 15, 2026 | 2.458B |
| October 14, 2026 | 2.383B |
| October 13, 2026 | 2.468B |
| Date | Value |
|---|---|
| October 12, 2026 | 2.556B |
| October 09, 2026 | 2.636B |
| October 08, 2026 | 2.511B |
| October 07, 2026 | 2.590B |
| October 06, 2026 | 2.609B |
| October 05, 2026 | 2.710B |
| October 02, 2026 | 2.724B |
| October 01, 2026 | 2.809B |
| September 30, 2026 | 2.832B |
| September 29, 2026 | 2.652B |
| September 28, 2026 | 2.679B |
| September 25, 2026 | 2.585B |
| September 24, 2026 | 2.597B |
| September 23, 2026 | 2.596B |
| September 22, 2026 | 2.778B |
| September 21, 2026 | 2.597B |
| September 18, 2026 | 2.478B |
| September 17, 2026 | 2.543B |
| September 16, 2026 | 2.532B |
| September 15, 2026 | 2.583B |
| September 14, 2026 | 2.717B |
| September 11, 2026 | 2.696B |
| September 10, 2026 | 2.746B |
| September 09, 2026 | 2.773B |
| September 08, 2026 | 2.855B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Oncolytics Biotech, Inc. | 42.92M |
| Sangamo Therapeutics, Inc. | 36.86M |
| Sarepta Therapeutics, Inc. | 1.797B |
| Anixa Biosciences, Inc. | 73.23M |
| Vicapsys Life Sciences, Inc. | 16.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 70.13M |
| Revenue (Quarterly) | 17.78M |
| Total Expenses (Quarterly) | -52.35M |
| EPS Diluted (Quarterly) | 0.3651 |
| Gross Profit Margin (Quarterly) | 73.66% |
| Earnings Yield | -9.65% |
| Normalized Earnings Yield | -9.651 |